Related Experiment Video
Updated: Jul 25, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
Published on: August 4, 2012
[Experimental study on platelet activating factor and systemic circulatory failure caused by ischemic liver]
T Fukuoka1, Y Nakajima, H Nakano
1First Department of Surgery, Nara Medical University, Kashihara, Japan.
Ischemic liver releases platelet-activating factor (PAF), causing circulatory depression. Administering a PAF antagonist effectively prevented this systemic circulatory failure in dogs, suggesting a potential therapeutic target.
Area of Science:
- Cardiovascular Physiology
- Hepatology
- Immunology
Context:
- Systemic circulatory failure frequently accompanies ischemic hepatic failure.
- Retransplantation can resolve circulatory derangements in hepatic graft failure, hinting at a liver-derived factor.
- The precise mechanism of circulatory depression post-liver ischemia requires elucidation.
Purpose:
- To investigate the role of platelet-activating factor (PAF) in systemic circulatory failure following liver ischemia.
- To assess the efficacy of a PAF antagonist in mitigating circulatory collapse induced by liver ischemia.
Summary:
- Partial hepatic ischemia was induced in dogs, followed by resection of non-ischemic lobes.
- One group received a PAF antagonist (CV6209) intravenously, while the control group received saline.
- The control group exhibited significant decreases in mean arterial pressure and mortality, whereas the PAF antagonist group maintained stable blood pressure and showed no mortality.
Impact:
- Ischemic liver tissue appears to release PAF, which contributes to systemic circulatory depression.
- PAF antagonists demonstrate potential as therapeutic agents for managing circulatory dysfunction associated with ischemic liver injury.
- This study provides evidence for PAF's critical role in the pathophysiology of ischemic liver-induced circulatory failure.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology

